Identification and clinical management of persons with chronic hepatitis C virus infection — Cherokee nation, 2012–2015

Morbidity and Mortality Weekly Report

Volumn 65, Issue 18, 2016, Pages 461-466

  Mera, Jorge ^a   Vellozzi, Claudia ^b   Hariri, Susan ^b   Carabin, Hélène ^c   Drevets, Douglas A ^c,d   Miller, Anna ^a   Reilley, Brigg ^e   Essex, Whitney ^a   Gahn, David ^a   Lyons, Lisa ^a   Leston, Jessica ^f   Ward, John W ^b  

^a Cherokee Nation Health Service   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e INDIAN HEALTH SERVICE   (United States)

^f Northwest Portland Area Indian Health Board   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGED; AMERICAN INDIAN; COHORT ANALYSIS; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; HEALTH DISPARITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MASS SCREENING; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; ORGANIZATIONAL POLICY; PUBLIC HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEALTH STATUS DISPARITIES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INDIANS, NORTH AMERICAN; MALE; MASS SCREENING; MIDDLE AGED; ORGANIZATIONAL POLICY; RNA, VIRAL; UNITED STATES; UNITED STATES INDIAN HEALTH SERVICE; YOUNG ADULT;

EID: 84969556093     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6518a2     Document Type: Article

References (10)

1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015;62:1353–63. http://dx.doi.org/10.1002/hep.27978
2. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis 2014;58:40–9. http://dx.doi.org/10.1093/cid/cit642
3. CDC. Viral hepatitis surveillance, United States; 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2014. http://www.cdc.gov/hepatitis/statistics/2013surveillance/pdfs/2013hepsurveillancerpt.pdf
4. Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: a meta-analysis. World J Hepatol 2015;7:806–13. http://dx.doi.org/10.4254/wjh.v7.i5.806
5. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 2012;61(No. RR-4).
6. US Preventive Services Task Force. Final recommendation statement, hepatitis C: screening; 2013. Rockville, MD: US Preventive Services Task Force; 2013. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening
7. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011;364:2199–207. http://dx.doi.org/10.1056/NEJMoa1009370
8. Mitruka K, Thornton K. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model—Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep 2014;63:393–8.
9. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–6. http://dx.doi.org/10.1002/hep.21669
10. National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Washington, DC: The National Academies Press. http://www.nap.edu/read/23407/chapter/1